Poxel S.A. (EPA:POXEL)
0.3200
+0.0095 (3.06%)
Aug 26, 2025, 4:39 PM CET
Poxel Employees
Poxel had 6 employees as of December 31, 2023. The number of employees decreased by 31 or -83.78% compared to the previous year.
Employees
6
Change (1Y)
-31
Growth (1Y)
-83.78%
Revenue / Employee
€364,667
Profits / Employee
€2,684,167
Market Cap
16.66M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6 | -31 | -83.78% |
Dec 31, 2022 | 37 | -18 | -32.73% |
Dec 31, 2021 | 55 | 5 | 10.00% |
Dec 31, 2020 | 50 | 3 | 6.38% |
Dec 31, 2019 | 47 | 14 | 42.42% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
EssilorLuxottica Société anonyme | 153,498 |
Sanofi | 82,878 |
Sartorius Stedim Biotech | 9,901 |
bioMérieux | 14,754 |
Eurofins Scientific SE | 62,696 |
Ipsen | 5,358 |
ABIVAX Société Anonyme | 69 |
Virbac | 6,365 |
Poxel News
- 25 days ago - Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance - Business Wire
- 4 weeks ago - Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading - Business Wire
- 2 months ago - Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update - Business Wire
- 2 months ago - Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference - Business Wire
- 3 months ago - New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society - Benzinga
- 3 months ago - Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025 - Business Wire
- 3 months ago - Poxel S.A. reports Q1 results - Seeking Alpha
- 3 months ago - Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update - Business Wire